AR and posterior cortical atrophy: RB loss was reported in approximately 5% of primary PCa cases; this increases to over 30% in metastatic CRPC cases and more than 70% in neuroendocrine PCa (NEPC) cases, which are resistant to the androgen receptor–targeted (AR-targeted) therapies and have very limited treatment options available (19, 20).